What Are These Peptides?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) — a hormone naturally produced by the hypothalamus that stimulates the pituitary gland to secrete growth hormone. Ipamorelin is a growth hormone secretagogue that stimulates growth hormone release through a different mechanism: the ghrelin receptor pathway. When combined, they stimulate growth hormone release through two complementary pathways, producing a more robust and physiologically natural pulse of growth hormone than either compound alone.
Why They Are Combined
GHRH (mimicked by CJC-1295) and ghrelin agonism (mimicked by Ipamorelin) work synergistically. GHRH stimulates the production and release of growth hormone from pituitary cells. Ghrelin agonism amplifies the signal and increases the number of pituitary cells that respond to GHRH. Together, they produce a more complete stimulation of the natural growth hormone axis than either peptide alone, while maintaining the pulsatile pattern of GH release that mirrors the body's natural rhythm.
Potential Effects on GLP-1 Users
For people on GLP-1 therapy, the theoretical appeal of CJC-1295/Ipamorelin is its potential to support the aspects of body composition and recovery that GLP-1 works against. Growth hormone promotes fat oxidation, supports lean muscle maintenance, improves sleep quality (particularly deep sleep), and supports recovery. These effects are directly relevant to the challenges of rapid weight loss on GLP-1 — particularly muscle preservation and sleep quality.
2026 Regulatory Context
Peptide Regulatory Landscape (2026): CJC-1295 and Ipamorelin were among the peptides placed on the FDA's Category 2 restricted list in 2023, ending their availability through licensed compounding pharmacies. In February 2026, the FDA under the current administration began signaling openness to reclassifying certain previously restricted peptides. In July 2026, an FDA advisory committee voted to recommend that several peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) be added back to the 503A compounding list — though CJC-1295 and Ipamorelin were not among those reviewed in this round. Final FDA rulemaking for the reviewed peptides is expected no earlier than 2027. Access to CJC-1295 and Ipamorelin through licensed US compounding pharmacies remains restricted at this time.
CJC-1295 With DAC vs. Without DAC
CJC-1295 is available in two forms: with DAC (Drug Affinity Complex) and without DAC. The DAC form has a much longer half-life, allowing less frequent dosing but producing less physiological GH pulses. The version without DAC more closely mimics natural GHRH and is typically paired with Ipamorelin for injection two to three times daily — often at night to coincide with the body's natural nocturnal GH peak.